Satellos receives FDA IND clearance for FSHD drug forazapadin and secures up to $5 million in non-dilutive financing

Filing content

Satellos received FDA clearance for its IND application for forazapadin in FSHD and agreed to receive up to US$5 million in non-dilutive financing from the FSHD Canada Foundation.